Corvus Pharmaceuticals, Inc.

CRVS

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Nov 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Soquelitinib	Phase 3	Peripheral T-Cell Lymphoma, Not Otherwise Specified	-

Catalyst Timeline

1 upcoming, 0 past

⭐Phase 3Next

November 2026~Soquelitinib

Primary completion for Soquelitinib trial (NCT06561048) in Peripheral T-Cell Lymphoma, Not Otherwise Specified

Regulatory Approvals

CRVS News